Blood-based assays for site-specific tau phosphorylation-based diagnostics and therapies

Abstract

The present disclosure provides for using a blood sample to quantify tau phosphorylation at a particular amino acid residue to predict the time from the onset of mild cognitive impairment caused by Alzheimer's disease, staging Alzheimer's disease, guiding treatment decisions, and determining the onset of cognitive impairment caused by Alzheimer's disease. Methods of selecting subjects of a clinical trial and assessing the clinical efficacy of certain therapeutic interventions.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims priority to US Provisional Application No. 62 / 898,407, filed September 10, 2019, the disclosure of which is incorporated herein by reference. [0003] government rights [0004] This invention was made with government support under NS095773 awarded by the National Institutes of Health. The US Government has certain rights in this invention. [0005] Reference to Sequence Listing [0006] This application contains a Sequence Listing which has been filed in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy was created on September 10, 2020, named 665441_ST25.txt, and is 24 KB bytes in size. Background technique [0007] Microtubule-associated protein tau (MAPT or tau ) plays an important role in the morphology and physiology of neurons. Tau has six distinct isoforms of the full-length protein and undergoes many possible post-translational modifica...

AI Technical Summary

Problems solved by technology

However, the poor correlation between plasma tau and CSF tau levels has been a challenge in developing plasma tau as a biomarker for AD

Images